RxDoctor Payments Data

Gabriel Umana, MD

Family Medicine · Ocala, FLNPI 1508836628

Payments from drug & device makers

$2,964in general payments, 2019–2025

Across 170 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$514
  • Novo Nordisk$347
  • Lilly USA, LLC$247
  • Pfizer$200
  • Amgen$188
  • Exact Sciences$172
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,964 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$208,155
Medicare patients
438
Services billed
3,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$125,514
JardianceEmpagliflozin71$98,412
OzempicSemaglutide55$75,905
JanuviaSitagliptin Phosphate44$50,015
MounjaroTirzepatide39$47,911
XareltoRivaroxaban25$36,712
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$24,356
TradjentaLinagliptin19$24,194
MyrbetriqMirabegron22$22,473
JanumetSitagliptin Phos/Metformin Hcl11$15,162
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$12,980
Combivent RespimatIpratropium/Albuterol Sulfate15$9,476
BelsomraSuvorexant14$8,945
VascepaIcosapent Ethyl14$7,086
Atorvastatin Calcium692$6,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$121$132,082105 claims
PfizerEliquis$200$125,514136 claims
Novo NordiskOzempic$347$75,90555 claims
MerckJanuvia, Janumet, Belsomra$41$74,12269 claims
Lilly USA, LLCMounjaro$247$47,91139 claims
Johnson & JohnsonXarelto$127$36,71225 claims
GSKTrelegy Ellipta$81$24,35618 claims
Astellas Pharma US IncMyrbetriq$132$22,47322 claims
AbbVieSynthroid$514$3,70255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →